My lab researches how the human brain processes social and affective information and how these processes are affected in psychiatric disorders, especially schizophrenia and bipolar disorder. We use behavioral, electrophysiological (EEG), neuroimaging (functional MRI), eye tracking, brain stimulation (TMS, tACS), and computational methods in our studies. One main focus of our work is building and validating computational models based on intensive, high-dimensional subject-level behavior and brain data to explain clinical phenomena, parse mechanisms, and predict patient outcome. The goal is to improve diagnostic and prognostic assessment, and to develop personalized treatments.
Dr. Hadjiyski research interests include computer-aided diagnosis, artificial intelligence (AI), machine learning, predictive models, image processing and analysis, medical imaging, and control systems. His current research involves design of decision support systems for detection and diagnosis of cancer in different organs and quantitative analysis of integrated multimodality radiomics, histopathology and molecular biomarkers for treatment response monitoring using AI and machine learning techniques. He also studies the effect of the decision support systems on the physicians’ clinical performance.
Multi-center clinical trials increasingly utilize quantitative diffusion imaging (DWI) to aid in patient management and treatment response assessment for translational oncology applications. A major source of systematic bias in diffusion was discovered originating from platform-dependent gradient hardware. Left uncorrected, these biases confound quantitative diffusion metrics used for characterization of tissue pathology and treatment response leading to inconclusive findings, and increasing the requisite subject numbers and trial cost. We have developed technology to mitigate systematic diffusion mapping bias that exists on MRI scanners and are in process of deploying this technology for multi-center clinical trials. Another major source of variance and bottleneck in high-throughput analysis of quantitative diffusion maps is segmentation of tumor/tissue volume of interest (VOI) based on intensities and patterns on multi-contrast MR image datasets, as well as reliable assessment of longitudinal change with disease progression or response to treatment. Our goal is development/trial/application AI algorithms for robust (semi-) automated VOI definition in analysis of multi-dimensional MR datasets for oncology trials.
My group investigates hypertension using a principally patient-oriented approach, with key aspects of our work being collaborative with data scientists. For example, I collaborated with Casey Greene, PhD, computational biologist, on a project using generative adversarial neural networks to create a privacy-preserving dataset derivative of the SPRINT hypertension clinical trial. The work incorporated concepts from the differential privacy field, and the intent is to make clinical trial data sharing more feasible.
I build data science tools to address challenges in medicine and clinical care. Specifically, I apply signal processing, image processing and machine learning techniques, including deep convolutional and recurrent neural networks and natural language processing, to aid diagnosis, prognosis and treatment of patients with acute and chronic conditions. In addition, I conduct research on novel approaches to represent clinical data and combine supervised and unsupervised methods to improve model performance and reduce the labeling burden. Another active area of my research is design, implementation and utilization of novel wearable devices for non-invasive patient monitoring in hospital and at home. This includes integration of the information that is measured by wearables with the data available in the electronic health records, including medical codes, waveforms and images, among others. Another area of my research involves linear, non-linear and discrete optimization and queuing theory to build new solutions for healthcare logistic planning, including stochastic approximation methods to model complex systems such as dispatch policies for emergency systems with multi-server dispatches, variable server load, multiple priority levels, etc.
In his various roles, he has helped develop several educational programs in Innovation and Entrepreneurial Development (the only one of their kind in the world) for medical students, residents, and faculty as well as co-founding 4 start-up companies (including a consulting group, a pharmaceutical company, a device company, and a digital health startup) to improve the care of surgical patients and patients with cancer. He has given over 80 invited talks both nationally and internationally, written and published over 110 original scientific articles, 12 book chapters, as well as a textbook on “Success in Academic Surgery: Innovation and Entrepreneurship” published in 2019 by Springer-NATURE. His research is focused on drug development and nanoparticle drug delivery for cancer therapeutic development as well as evaluation of circulating tumor cells, tissue engineering for development of thyroid organoids, and evaluating the role of mixed reality technologies, AI and ML in surgical simulation, education and clinical care delivery as well as directing the Center for Surgical Innovation at Michigan. He has been externally funded for 13 consecutive years by donors and grants from Susan G. Komen Foundation, the American Cancer Society, and he currently has funding from three National Institute of Health R-01 grants through the National Cancer Institute. He has served on several grant study sections for the National Science Foundation, the National Institute of Health, the Department of Defense, and the Susan G. Komen Foundation. He also serves of several scientific journal editorial boards and has serves on committees and leadership roles in the Association for Academic Surgery, the Society of University Surgeons and the American Association of Endocrine Surgeons where he was the National Program Chair in 2013. For his innovation efforts, he was awarded a Distinguished Faculty Recognition Award by the University of Michigan in 2019. His clinical interests and national expertise are in the areas of Endocrine Surgery: specifically thyroid surgery for benign and malignant disease, minimally invasive thyroid and parathyroid surgery, and adrenal surgery, as well as advanced Melanoma Surgery including developing and running the hyperthermic isolated limb perfusion program for in transit metastatic melanoma (the only one in the state of Michigan) which is now one of the largest in the nation.
Dr. Fernandez is a clinical psychologist with extensive training in both addiction and behavioral medicine. She is the Clinical Program Director at the University of Michigan Addiction Treatment Service. Her research focuses on the intersection of addiction and health across two main themes: 1) Expanding access to substance use disorder treatment and prevention services particularly in healthcare settings and; 2) applying precision health approaches to addiction-related healthcare questions. Her current grant-funded research includes an NIH-funded randomized controlled pilot trial of a preoperative alcohol intervention, an NIH-funded precision health study to leverage electronic health records to identify high-risk alcohol use at the time of surgery using natural language processing and other machine-learning based approaches, a University of Michigan funded precision health award to understand and prevent new persistent opioid use after surgery using prediction modeling, and a federally-funded evaluation of the state of Michigan’s substance use disorder treatment expansion.
Niko Kaciroti is a Research Scientist at the Departments of Pediatrics and Biostatistics. He received his PhD in Biostatistics from the University of Michigan. Since then he has collaborated in multidisciplinary research at the University of Michigan and with researchers from other universities in the United States and internationally. Dr. Kaciroti is a faculty member at the Center for Computational Medicine and Bioinformatics. His main research interest is in using Bayesian models for analyzing longitudinal data from clinical trials with missing values, as well as using Bayesian methods for nonlinear and dynamic models. Dr. Kaciroti is an elected member of the International Statistical Institute and serves as statistical editor for the American Journal of Preventive Medicine and the International Journal of Behavior Nutrition and Physical Activity.
Dr. Saran is an internationally recognized expert in kidney disease research – specifically, in the area of kidney disease surveillance and epidemiology. From 2014 – 2019, he served as Director of the United States Renal Data System (USRDS; www.usrds.org), a ‘gold standard’ for kidney disease data systems, worldwide. Since 2006 he has been Co-Principal Investigator for the Centers for the Disease Control and Prevention’s (CDC’s) National CKD Surveillance System for the US, a one of a kind project that complements the USRDS, while focusing on upstream surveillance of CKD and its risk factors (www.cdc.org/ckd/surveillance). Both projects have influenced policy related to kidney disease in the US and were cited extensively in the July 2019 Advancing American Kidney Health Federal policy document. Dr. Saran led the development of the first National Kidney Disease Information System (VA-REINS), for the Department of Veterans Affairs (VA), funded by the VA’s Center for Innovation, and one that led to the VA recognizing the importance of kidney disease as a health priority for US veterans. Dr. Saran has recently (2018-2021) been funded on a spin off project from VA REINS for investigation of ‘hot-spot’ of kidney disease among US Veterans involving both risk-prediction and geospatial analyses – a modern approach to health system big data being used for prevention and population health improvement, using kidney disease as an example. This approach has broad application for prevention and optimizing management of major chronic diseases.
My research primarily focuses on the following main themes: 1) development of methods for risk prediction and analyzing treatment effect heterogeneity, 2) Bayesian nonparametrics and Bayesian machine learning methods with a particular emphasis on the use of these methods in the context of survival analysis, 3) statistical methods for analyzing heterogeneity in risk-benefit profiles and for supporting individualized treatment decisions, and 4) development of empirical Bayes and shrinkage methods for high-dimensional statistical applications. I am also broadly interested in collaborative work in biomedical research with a focus on the application of statistics in cancer research.